Kantor and colleagues from the Hospital for Sick Children in Toronto, Canada have reported that outcomes for medically treated pediatric patients with dilated cardiomyopathy (DCM) have not changed over a 30-year period, despite institution of neurohormonal inhibition therapy. These findings are placed in the context of the worldwide experience of pediatric DCM and the limited number of studies of neurohormonal inhibition therapy in children with heart failure.
